Compare GNT & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | STXS |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.6M | 139.3M |
| IPO Year | N/A | 2004 |
| Metric | GNT | STXS |
|---|---|---|
| Price | $8.42 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 39.4K | ★ 521.9K |
| Earning Date | 01-01-0001 | 08-11-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $6.04 |
| Revenue Next Year | N/A | $33.01 |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.68 | $1.00 |
| 52 Week High | $9.38 | $3.15 |
| Indicator | GNT | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 21.13 |
| Support Level | $8.20 | N/A |
| Resistance Level | $8.57 | $1.97 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.50 | 13.31 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.